Gastroenterology Today Autumn 2023

More documents

Recommendations

Info

NEWS Severe bowel condition on the rise in the UK Many people suffer with the condition for years but the correct diagnosis and treatment can make a huge difference. [8] continue to raise awareness and invest in research to improve diagnosis and treatments.” Professor Chris Probert, Professor of • Resource for patients published by the national charity Guts UK highlights the growing number of microscopic colitis cases in the UK. Victoria, age 33 from London, was diagnosed with microscopic colitis last year. She said: <strong>Gastroenterology</strong> at the University of Liverpool said: • The charity has raised concerns about the number of people suffering with a misdiagnosis or living with undiagnosed and debilitating symptoms. • 17,000 new cases are being diagnosed each year, but the real number could be a lot higher. Experts have raised concerns about the number of people suffering with undiagnosed microscopic colitis, a debilitating bowel condition thought to affect thousands of adults in the UK. The national charity Guts UK has published a resource for patients during Microscopic Colitis Awareness Week to raise awareness of the disease and is calling for more research into prevention, faster diagnoses and developments in treatments. “I spent 12 years living with undiagnosed microscopic colitis. On my worst days, I was going to the toilet 30 to 40 times per day and suffered from awful stomach cramps. I ended up becoming agoraphobic because I was so distressed. I went to the doctor again and again but it took me all these years to get a correct diagnosis. I even went to A&E but was told it was ‘just IBS’ and I was sent home with no treatment plan. “By 2022 I became scared of eating in case it triggered symptoms and my flare ups were becoming more frequent. I felt more tired than I’d ever felt in my life and completely hopeless. I was also trying to parent my baby son while living with the condition. “The treatment I have received after getting my diagnosis has changed my life. I feel like I’ve regained some semblance of normal.” “Undiagnosed microscopic colitis can cause years of unnecessary suffering. The diarrhoea symptoms tend to be very severe and houselimiting leading to considerable distress for patients. “It’s not clear why cases of the condition are on the increase but it is likely to be due to a mixture of increased awareness of symptoms leading to more diagnoses and environmental factors such as a potential side effect of common prescription drugs such as some antidepressants. “The good news is that effective treatments are available so people experiencing symptoms could benefit enormously by talking with their GP.” Resources published in March 2022 by Guts UK to raise awareness of microscopic colitis showed that women are 700% more likely than men to suffer with the condition. Microscopic colitis is an inflammation of the large intestine (bowel) that causes persistent, frequent and watery diarrhoea (throughout the day and night), stomach pain, fatigue, faecal incontinence and weight loss. It is frequently misdiagnosed and the prevalence of the condition is higher than previously thought. [1] Microscopic colitis is named because, unlike other inflammatory bowel diseases, like Crohn’s disease or ulcerative colitis, it can’t be diagnosed with a colonoscopy alone and a sample of tissue taken from the bowel must be examined under a microscope to identify the condition. Because of this, the disease is often misdiagnosed. The causes of microscopic colitis are still unclear. As it is a relatively new disease (first described in 1976) it has led to a presumption that it is environmental as opposed to genetic factors that are responsible for its occurrence. For more information visit gutscharity.org.uk GASTROENTEROLOGY TODAY – AUTUMN <strong>2023</strong> Scientists estimate that around 67,000 people are living with microscopic colitis in the UK or at least 1 in 1,000 adults.[2][3] 17,000 new cases are being diagnosed each year, but the real number could be a lot higher because it’s often underreported and misdiagnosed.[4] A 2012 study showed that one in three patients with microscopic colitis were initially incorrectly diagnosed with Irritable Bowel Syndrome (IBS) and “a large, hidden burden of undiagnosed and untreated microscopic colitis likely exists in the UK population owing to systematic misdiagnosis of microscopic colitis as IBS.”[5][6] Despite the missed diagnoses, cases of microscopic colitis are on the rise globally. The UK incidence rate of microscopic colitis in 2016 was twice that observed in 2009.[7] Microscopic colitis is a leading cause of diarrhoea in older adults and it can have a devastating impact on a person’s quality of life. Julie Harrington, CEO of Guts UK, said: “It’s terribly sad that thousands of people are suffering with the debilitating symptoms of microscopic colitis. Most people with the condition can be easily treated with a course of gut-specific steroids or with symptom-relieving medicines but getting a diagnosis is the first, essential step. “People living with the condition but without the benefit of a correct diagnosis and effective treatments often can often feel very isolated due to the urgent nature of their symptoms and their need to be near to toilet facilities at all times. We know that this can also have a detrimental effect on their mental wellbeing. “The rates of microscopic colitis are increasing and are likely to grow further as the population ages, so it’s crucial that we identify risk factors, provide specific training for healthcare providers, #MicroscopicColitisAwareness [1] Undiagnosed microscopic colitis: a hidden cause of chronic diarrhoea and a frequently missed treatment opportunity: https://fg.bmj.com/ content/11/3/228 [2] Aprox. 67,000 people are living with Microscopic Colitis in the UK - around 58,600 women and 8,400 men. [3] Microscopic colitis includes two related inflammatory bowel disorders, lymphocytic colitis and collagenous colitis that have a combined prevalence of 103 cases per 100 000 population: May 2019. [4] https://www.crohnsandcolitis.org.uk/aboutcrohns-and-colitis/publications/microscopiccolitis [5] https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3484793/ [6] https://drive.google.com/file/d/1XF- FoJM3wGeoO1krPzh-aQiACXSYwPSf/ view?usp=sharing [7] https://gut.bmj.com/content/66/Suppl_2/A156.1 [8] https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC8776530/ [9] 87.5% of people suffering with the condition are female - most of whom are diagnosed between the ages of 50 and 70. 24
Revolutionise Your Your IBD Revolutionise Management: IBD Your IBD Revo M BDoc IBDoc ® Calprotectin ® Calprotectin Home IBDoc Home Test ® Calprotectin with Test with Hom IB Swift, Swift, Direct Direct to Patient to Patient Swift, Delivery Direct Delivery to Patien Discover the Discover future of the future of healthcare at healthcare your at your doorstep with doorstep our with our all-new direct all-new to patient direct to patient Discover the future of healthcare at your doorstep with our all-new direct to patient kit delivery for kit the delivery IBDoc for the IBDoc Elevate ® Your Elevate Your kit delivery for the IBDoc ® Elevate Yo ctin self-testing calprotectin system. self-testing This solution system. This solution calprotectin Healthcare self-testing Approach Healthcare system. Approach This solution calprotectin Healthcar rs both empowers patients both and patients clinicians, and redefining clinicians, redefining empowers with Seamless both with patients Remote Seamless and clinicians, Remote redefining empowers with Seam b agement. IBD management. IBD Testing management. using Testing the BUHLMANN using the IBDoc BUHLMANN : IBDoc ® : IBD Testing manage us ves requirement f Removes for requirement administrative for logistics administrative logistics f fRemoves Excellent requirement correlation f Excellent for with administrative correlation laboratory with logistics laboratory f fRemoves Excellen r ding kits to in sending patients kits to patients in tests sending and kits endoscopic to tests patients and findings endoscopic findings in sending tests an ves shelf f life Improves and stock shelf level life and management stock level management f fImproves Swift quantitative shelf flife Swift and testing, quantitative stock level giving management testing, results giving results f fImproves Swift qu s ed deliveries: f Tracked deliveries: f Tracked the same deliveries: day for the the same clinical day team for the and clinical the patient team and the patient f Tracked the sam de eekly reports Z Weekly of dispatch reports requests of dispatch available requests availablef Z Minimized Weekly reports pre-analytical f Minimized of dispatch errors pre-analytical requests thanks available to errors simple thanks to simple fZ Minimiz Weekl sample preparation sample preparation sample illing only Zwhen Billing kits are only sent when out kits are sent out Z Billing only when kits are sent out Z Billing f Individualised f kit Individualised containing everything kit containing the patient everything the patient f Individu le delivery f Flexible options delivery (number options of kits (number and location) of kits and location) f Flexible needs delivery for a single options needs test for (number a single of test kits and location) f Flexible needs de f ers in As innovative pioneers in healthcare innovative healthcare As pioneers in innovative healthcare As pioneers i , we're solutions, proud to we're announce proud to our announce our solutions, we're proud to announce our solutions, we approach enhanced to approach home testing to home logistics. testing logistics. Elevate enhanced your Elevate approach IBD management your to home IBD management testing today logistics. today Elevate enhanced your ap IB boratories Alpha Laboratories now presents now the presents the Reach Alpha out Laboratories Reach us at out digestivedx@alphalabs.co.uk now to us presents at the Reach Alpha out Labora to us ity for opportunity direct IBDoc for ® direct kit delivery, IBDoc ® kit delivery, opportunity for direct IBDoc ® kit delivery, opportunity he patients’ right to the homes. patients’ homes. right to the patients’ homes. right to the p 3000 02380 • sales@alphalabs.co.uk 483000 • sales@alphalabs.co.uk • www.alphalabs.co.uk • www.alphalabs.co.uk 02380 483000 • sales@alphalabs.co.uk • www.alphalabs.co.uk 02380 48300
Page 1 and 2: Volume 34 No. 3 Autumn 2023 THE BES
Page 3 and 4: CONTENTS CONTENTS Gastroenterology
Page 5 and 6: TRIAGE GASTROSCOPY REFERRALS WITH G
Page 7 and 8: Mesalazine optimisation can increas
Page 9 and 10: FEATURE A liver ultrasound was norm
Page 11 and 12: Optimising maintenance therapy for
Page 13 and 14: FEATURE fatigue over time is indepe
Page 15 and 16: FEATURE Fig. 1 Mean fatigue scores
Page 17 and 18: FEATURE Fig. 3 Correlation of fatig
Page 19 and 20: FEATURE studies are in agreement wi
Page 21: FEATURE 26. De Vries J, Michielsen
Page 26 and 27: NEWS Inflammatory bowel disease tre
Page 28 and 29: COMPANY NEWS GASTROENTEROLOGY TODAY
Page 30 and 31: COMPANY NEWS GASTROENTEROLOGY TODAY
Page 32: Helicobacter Test INFAI ® One of t

Gastroenterology Today Autumn 2023

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?